Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Jun;37(6):597–604. doi: 10.1111/j.1365-2125.1994.tb04310.x

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.

T Andersson 1, J O Miners 1, M E Veronese 1, D J Birkett 1
PMCID: PMC1364821  PMID: 7917780

Abstract

1. The in vitro metabolism of omeprazole was studied in human liver microsomes in order to define the secondary metabolic pathways and identify the cytochrome P450 (CYP) isoforms responsible for the formation of the secondary metabolites of omeprazole. 2. The major secondary omeprazole metabolite was the hydroxysulphone, which was formed during incubation with both hydroxyomeprazole and omeprazole sulphone. A second metabolite, tentatively identified as pyridine-N-oxide omeprazole sulphone, was also formed during incubation with omeprazole sulphone. The formation kinetics of these two metabolites from omeprazole sulphone were biphasic suggesting the involvement of multiple CYP isoforms in each case. In contrast, the formation kinetics of hydroxysulphone from hydroxyomeprazole were linear. 3. Inhibition studies, performed with omeprazole sulphone as substrate at concentrations at which the high affinity activities predominated, with a series of isoform selective inhibitors as well as with an anti-CYP2C3 antibody suggested a dominant role of S-mephenytoin hydroxylase in the formation of hydroxysulphone from omeprazole sulphone. By contrast, CYP3A activities were predominant in the formation of hydroxysulphone from hydroxyomeprazole as well as in the formation of pyridine-N-oxide omeprazole sulphone from omeprazole sulphone.

Full text

PDF
597

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson T., Cederberg C., Edvardsson G., Heggelund A., Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther. 1990 Jan;47(1):79–85. doi: 10.1038/clpt.1990.12. [DOI] [PubMed] [Google Scholar]
  2. Andersson T., Lagerstrøm P. O., Miners J. O., Veronese M. E., Weidolf L., Birkett D. J. High-performance liquid chromatographic assay for human liver microsomal omeprazole metabolism. J Chromatogr. 1993 Sep 22;619(2):291–297. doi: 10.1016/0378-4347(93)80119-o. [DOI] [PubMed] [Google Scholar]
  3. Andersson T., Miners J. O., Veronese M. E., Tassaneeyakul W., Tassaneeyakul W., Meyer U. A., Birkett D. J. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol. 1993 Dec;36(6):521–530. doi: 10.1111/j.1365-2125.1993.tb00410.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Andersson T., Regårdh C. G., Dahl-Puustinen M. L., Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit. 1990 Jul;12(4):415–416. doi: 10.1097/00007691-199007000-00020. [DOI] [PubMed] [Google Scholar]
  5. Andersson T., Regårdh C. G., Lou Y. C., Zhang Y., Dahl M. L., Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics. 1992 Feb;2(1):25–31. doi: 10.1097/00008571-199202000-00005. [DOI] [PubMed] [Google Scholar]
  6. Bardhan K. D., Bianchi Porro G., Bose K., Daly M., Hinchliffe R. F., Jonsson E., Lazzaroni M., Naesdal J., Rikner L., Walan A. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol. 1986 Aug;8(4):408–413. doi: 10.1097/00004836-198608000-00005. [DOI] [PubMed] [Google Scholar]
  7. Doecke C. J., Veronese M. E., Pond S. M., Miners J. O., Birkett D. J., Sansom L. N., McManus M. E. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol. 1991 Feb;31(2):125–130. doi: 10.1111/j.1365-2125.1991.tb05499.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fellenius E., Berglindh T., Sachs G., Olbe L., Elander B., Sjöstrand S. E., Wallmark B. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase. Nature. 1981 Mar 12;290(5802):159–161. doi: 10.1038/290159a0. [DOI] [PubMed] [Google Scholar]
  9. Guengerich F. P., Kim D. H., Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol. 1991 Mar-Apr;4(2):168–179. doi: 10.1021/tx00020a008. [DOI] [PubMed] [Google Scholar]
  10. Guengerich F. P., Müller-Enoch D., Blair I. A. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986 Sep;30(3):287–295. [PubMed] [Google Scholar]
  11. Inaba T., Jurima M., Mahon W. A., Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos. 1985 Jul-Aug;13(4):443–448. [PubMed] [Google Scholar]
  12. Klinkenberg-Knol E. C., Jansen J. M., Festen H. P., Meuwissen S. G., Lamers C. B. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet. 1987 Feb 14;1(8529):349–351. doi: 10.1016/s0140-6736(87)91726-0. [DOI] [PubMed] [Google Scholar]
  13. Küpfer A., Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 1984;26(6):753–759. doi: 10.1007/BF00541938. [DOI] [PubMed] [Google Scholar]
  14. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  15. Lind T., Andersson T., Skånberg I., Olbe L. Biliary excretion of intravenous [14C] omeprazole in humans. Clin Pharmacol Ther. 1987 Nov;42(5):504–508. doi: 10.1038/clpt.1987.188. [DOI] [PubMed] [Google Scholar]
  16. Lind T., Cederberg C., Ekenved G., Haglund U., Olbe L. Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. Gut. 1983 Apr;24(4):270–276. doi: 10.1136/gut.24.4.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. McManus M. E., Burgess W. M., Veronese M. E., Huggett A., Quattrochi L. C., Tukey R. H. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res. 1990 Jun 1;50(11):3367–3376. [PubMed] [Google Scholar]
  18. Pessayre D., Tinel M., Larrey D., Cobert B., Funck-Brentano C., Babany G. Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione. J Pharmacol Exp Ther. 1983 Mar;224(3):685–691. [PubMed] [Google Scholar]
  19. Raney K. D., Shimada T., Kim D. H., Groopman J. D., Harris T. M., Guengerich F. P. Oxidation of aflatoxins and sterigmatocystin by human liver microsomes: significance of aflatoxin Q1 as a detoxication product of aflatoxin B1. Chem Res Toxicol. 1992 Mar-Apr;5(2):202–210. doi: 10.1021/tx00026a009. [DOI] [PubMed] [Google Scholar]
  20. Regårdh C. G., Andersson T., Lagerström P. O., Lundborg P., Skånberg I. The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. Ther Drug Monit. 1990 Mar;12(2):163–172. doi: 10.1097/00007691-199003000-00010. [DOI] [PubMed] [Google Scholar]
  21. Renberg L., Simonsson R., Hoffmann K. J. Identification of two main urinary metabolites of [14C]omeprazole in humans. Drug Metab Dispos. 1989 Jan-Feb;17(1):69–76. [PubMed] [Google Scholar]
  22. Robson R. A., Matthews A. P., Miners J. O., McManus M. E., Meyer U. A., Hall P. M., Birkett D. J. Characterisation of theophylline metabolism in human liver microsomes. Br J Clin Pharmacol. 1987 Sep;24(3):293–300. doi: 10.1111/j.1365-2125.1987.tb03172.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sesardic D., Boobis A. R., Murray B. P., Murray S., Segura J., de la Torre R., Davies D. S. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol. 1990 Jun;29(6):651–663. doi: 10.1111/j.1365-2125.1990.tb03686.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sohn D. R., Kobayashi K., Chiba K., Lee K. H., Shin S. G., Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther. 1992 Sep;262(3):1195–1202. [PubMed] [Google Scholar]
  25. Veronese M. E., Doecke C. J., Mackenzie P. I., McManus M. E., Miners J. O., Rees D. L., Gasser R., Meyer U. A., Birkett D. J. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J. 1993 Jan 15;289(Pt 2):533–538. doi: 10.1042/bj2890533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Walan A., Bader J. P., Classen M., Lamers C. B., Piper D. W., Rutgersson K., Eriksson S. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med. 1989 Jan 12;320(2):69–75. doi: 10.1056/NEJM198901123200201. [DOI] [PubMed] [Google Scholar]
  27. Wallmark B., Lorentzon P., Larsson H. The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro. Scand J Gastroenterol Suppl. 1985;108:37–51. [PubMed] [Google Scholar]
  28. Yamano S., Tatsuno J., Gonzalez F. J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 1990 Feb 6;29(5):1322–1329. doi: 10.1021/bi00457a031. [DOI] [PubMed] [Google Scholar]
  29. Yun C. H., Shimada T., Guengerich F. P. Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol. 1991 Nov;40(5):679–685. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES